Estimating loss of the wild-type p53 gene by in situ hybridization of fine-needle aspirates from breast carcinomas

Diagnostic Cytopathology

Volumn 20, Issue 5, 1999, Pages 266-270

  Sauer, Torill ^a   Beraki, Kahsai ^a   Furu, Irene ^a   Ormerod, Eli ^a   Jebsen, Peter W ^a   Næss, Oddvar ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast carcinoma; Chromosome 17; Fine needle aspirate; In situ hybridization; P53

Indexed keywords

PROTEIN P53;

ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER CYTODIAGNOSIS; CANCER GRADING; CHROMOSOME 17; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE ASSOCIATION; FIBROADENOMA; GENE ISOLATION; GENE LOSS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, P53; HUMANS; IN SITU HYBRIDIZATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032964072     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(199905)20:5<266::AID-DC4>3.0.CO;2-6     Document Type: Article

References (34)

1. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-416.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
3. Levine AJ, Momand J, Finlay CA. The p53 tumour-suppressor gene. Nature 1991;351:543-546.
4. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-355.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
6. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 1994;57:498-503.
7. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-935.
8. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen A-L. Prognostic significance of Tp53 alterations in breast carcinoma. Br J Cancer 1993;68:540-548.
9. Deng G, Chen L-C, Schott DR, et al. Loss of heterozygocity and p53 gene mutations in breast cancer. Cancer Res 1994;54:499-505.
10. Eyfjord J, Thorlacius S, Steinarsdottir M, Valgardsdottir R. Øgmundsdottir HM, Anamthawat-Jonsson K. P53 abnormalities and genomic instability in primary breast carcinomas. Cancer Res 1995;55:646-651.
11. Hurlimann J, Chaubert P, Benhattar J. P53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994;7(4):423-428.
12. Singh S, Simon M, Meybohm I, et al. Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genet 1993;90:635-640.
13. Sjøgren S, Ingarus M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88(3/4):173-181.
14. Gretarsdottir S, Tryggvadottir L, Jonasson JG, et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 1996;74:555-561.
15. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas: molecular and immunohistochemical analysis. APMIS 1997;105:121-130.
16. Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol 1996;5(3):187-193.
17. Leong AS-Y, Lee AKC. Biological indices in the assessment of breast cancer. J Clin Pathol 1995; 48:M221-M238.
18. Andersen TI, Gaustad A, Ottestad L, et al. Genetic alterations of the tumor suppressor gene regions 3p, 11p, 13q, 17q and 17p in human breast carcinomas. Genes Chromosom Cancer 1992;4:113-121.
19. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosom Cancer 1995;14:227-251.
20. Matsumura K, Kallioniemi A, Kallioniemi O-P, et al. Deletion of chromosome 17p loci in breast cancer cells detected by in situ hybridization. Cancer Res 1992;52:3474-3477.
21. Pandis N, Jin Y, Gorunova L, et al. Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosom Cancer 1995;12:173-185.
22. Watatani M, Nagayama K, Imanishi Y, et al. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. Breast Cancer Res Treat 1993;28(3):231-239.
23. Sauer T, Beraki K, Jebsen PW, Ormerod E, Næss O. Ploidy analysis by in situ hybridization of interphase cell nuclei in fine-needle aspirates from breast carcinomas: correlation with cytologic grading. Diagn Cytopathol 1997;17(4):267-271.
24. Cornelis RS, van Vliet M, Vos CBJ, et al. Evidence for a gene on 17.p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 1994;54:4200-4206.
25. Thompson AM, Andreson TJ, Condie A, et al. P53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992;50:528-532.
26. Børresen A-L, Andersen TI, Eyfjord JE, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosom Cancer 1995;14:71-75.
27. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutations detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93:1093-1096.
28. Thorlacius S, Thorgilsson B, Bjørnsson J, et al. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 1995;31A(11):1856-1861.
29. Robinson IA, McKee G, Nicholsen A, et al. Prognostic value of cytologic grading of fine-needle aspirates from breast carcinomas. Lancet 1994;343:947-949.
30. Li X, Tsuji T, Wen S, Mimura Y, Sasaki K, Shinozaki F. Detection of numeric abnormalites of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Cancer 1997;79(12):2314-2319.
31. Kobayashi M, Kawashima A, Mai M, Ooi A. Analysis of chromosome I7p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization. Am J Pathol 1996;149(5):1575-1584.
32. Sauter G, Deng G, Moch H, et al. Physical deletion of the p53 gene in bladder cancer: detection by fluorescence in situ hybridization. Am J Pathol 1994;144(4):756-766.
33. Matsyama H, Pan Y, Mahdy EA, et al. P53 deletion as a genetic marker in urothelial tumor by fluorescence in situ hybridization. Cancer Res 1994;54:6057-6060.
34. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-948.